Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesús F. San Miguel, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, William S. Dalton, Anthony Boral, Dixie Esseltine, Jane Porter, David P. Schenkein, Kenneth C. Anderson

New England Journal of Medicine, 2005

Dana-Farber Cancer Institute, Rotterdam University of Applied Sciences, NewYork–Presbyterian Hospital, University of Pennsylvania, Hôpital Claude Huriez, Hadassah Academic College, Emory University, University Hospital Heidelberg, Princess Margaret Hospital, Complejo Hospitalario de Salamanca, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, University of Turin, St Bartholomew's Hospital, Moffitt Cancer Center, Millennium Engineering and Integration (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2489

Citations

View on Google Scholar

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Abstract

Journal Details

Join JournalsHub

Welcome Back